Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials
Martín, M., Loibl, S., Hyslop, T., De la Haba-Rodríguez, J., Aktas, B., Cirrincione, C.T., Mehta, K., Barry, W.T., Morales, S., Carey, L.A., Garcia-Saenz, J.A., Partridge, A., Martinez-Jañez, N., HahnVolume:
117
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/j.ejca.2019.06.002
Date:
August, 2019
File:
PDF, 908 KB
english, 2019